Diabetes Mellitus May Increase Risk for Developing Heart Failure
Increased risk for heart failure also seen in group of participants without diastolic dysfunction
Metabolic
High Lipoprotein(a) Is Risk Factor for CVD in Type 1 Diabetes
Lp(a) is a significant risk factor for macrovascular disease, albuminuria, and calcified aortic valve disease for patients with type 1 diabetes.
Poor Diet Contributes Substantially to Cardiometabolic Disease Costs
Suboptimal diet accounts for 18.2 percent of all cardiometabolic disease costs in the United States.
Examining the Associations Between Oral Nitrate-Reducing Bacteria and Cardiometabolic Outcomes
A greater quantity of oral nitrate-reducing bacteria was found to be associated with reduced plasma glucose and insulin resistance in young to middle-aged adults.
ADA 2020 Standards of Care Incorporate CVD Risk Stratification, New Medications
The American Diabetes Association (ADA) has published an update to their Standards of Medical Care in Diabetes for 2020.
First-Episode Psychosis May Be a Key Intervention Point for Cardiometabolic Risk
Adverse cardiometabolic outcomes were more commonly observed among patients from black and ethnic minority groups compared with white patients.
Impact of Changes in Metabolic Syndrome Status on Risk for Major Adverse Cardiovascular Events
Associations were established between recovery from and development of metabolic syndrome and reduced and elevated risk for major adverse cardiovascular events, respectively.
Racial Differences Seen With Hypertrophic Cardiomyopathy
Racial differences in disease expression and adverse clinical outcomes exist between black and white patients with hypertrophic cardiomyopathy.
Addition of Evolocumab to Statin Therapy May Reduce LDL-C in Patients With ACS
In patients with acute coronary syndrome, the early in-hospital addition of evolocumab to high-dose statin therapy was found to be safe, well tolerated, and efficacious in reducing low-density lipoprotein cholesterol levels.
Metabolic Syndrome Status Linked to MACE Risk
The risk for MACE decreased with recovery from metabolic syndrome, while risk increased from metabolic syndrome development,
Next post in Metabolic
